Analysts Expect Jounce Therapeutics Inc (NASDAQ:JNCE) Will Announce Earnings of $2.34 Per Share

Wall Street analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to report earnings of $2.34 per share for the current quarter, Zacks reports. Four analysts have issued estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at $2.70 and the lowest estimate coming in at $1.83. Jounce Therapeutics posted earnings of ($0.23) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 1,117.4%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of $1.66 per share for the current fiscal year, with EPS estimates ranging from $1.12 to $2.28. For the next fiscal year, analysts anticipate that the business will post earnings of ($2.87) per share, with EPS estimates ranging from ($3.90) to ($1.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. Jounce Therapeutics had a negative return on equity of 29.64% and a negative net margin of 46.07%. The business had revenue of $17.45 million for the quarter, compared to analysts’ expectations of $17.09 million.

JNCE has been the topic of a number of analyst reports. ValuEngine cut Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. JPMorgan Chase & Co. reissued a “sell” rating on shares of Jounce Therapeutics in a report on Sunday, August 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $10.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JNCE. Meeder Asset Management Inc. grew its holdings in shares of Jounce Therapeutics by 249.6% during the second quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock worth $25,000 after buying an additional 3,594 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Jounce Therapeutics during the second quarter worth about $59,000. Algert Global LLC purchased a new position in shares of Jounce Therapeutics during the first quarter worth about $88,000. Bailard Inc. grew its holdings in shares of Jounce Therapeutics by 54.1% during the second quarter. Bailard Inc. now owns 22,800 shares of the company’s stock worth $113,000 after buying an additional 8,000 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Jounce Therapeutics by 37.4% during the fourth quarter. Bank of America Corp DE now owns 35,082 shares of the company’s stock worth $118,000 after buying an additional 9,544 shares during the last quarter. 73.32% of the stock is currently owned by hedge funds and other institutional investors.

Jounce Therapeutics stock traded up $0.06 during midday trading on Friday, reaching $3.57. The company’s stock had a trading volume of 1,088 shares, compared to its average volume of 107,405. Jounce Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $7.61. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20. The company has a market cap of $111.15 million, a P/E ratio of -4.24 and a beta of 3.51. The business has a 50-day simple moving average of $4.09 and a 200-day simple moving average of $4.96.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Recommended Story: How to interpret the current ratio

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.